By never freezing the locally produced CAR-T cells, disappointing response rates for relapsed/refractory CLL and Richter’s Syndrome patients are greatly improved
Combination ibrutinib-venetoclax-obinutuzumab provided short-term control for patients with Richter’s transformation, but responses were not durable.
Richter’s transformation is a rare very aggressive complication of CLL. Learn the role of stem cell transplants in treating Richter’s transformation.
Richter’s transformation is a rare complication of CLL and changes in how clinical trials are conducted might help patients access novel therapies.
Epcoritamab, a bispecific antibody, led to a 50% overall and 35% complete response rate in all Richter’s transformation patients.
For patients with Richter’s transformation, the combination of ibrutinib, venetoclax, and obinutuzumab may be most useful as a bridge to other therapies.
The combination therapy of tislelizumab plus zanubrutinib is effective and well-tolerated for patients with Richter’s transformation.
While the incidence of Richter’s transformation has not changed dramatically with the introduction of targeted therapies, those who received CLL / SLL treatment in the targeted therapy era appear to have a lower risk of Richter’s transformation.
Pirtobrutinib is a useful treatment option to temporarily manage Richter’s transformation, but long-term treatments are still needed.
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911
